SAGE-718 for Huntington Disease

Phase-Based Progress Estimates
Huntington Disease+1 More
SAGE-718 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will study whether SAGE-718 can improve cognition in people with Huntington's disease.

Eligible Conditions
  • Huntington Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Huntington Disease

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to approximately 112 days

Baseline and Day 84
Change From Baseline in the Huntington's Disease Cognitive Assessment Battery (HD-CAB) Composite Score
Change From Baseline in the UHDRS - Total Motor Score (TMS)
Change From Baseline in the Unified Huntington's Disease Rating Scale (UHDRS) - Independence Scale
Day 112
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Huntington Disease

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Experimental Treatment
Non-Treatment Group

178 Total Participants · 2 Treatment Groups

Primary Treatment: SAGE-718 · Has Placebo Group · Phase 2

Experimental Group · 1 Intervention: SAGE-718 · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 112 days

Who is running the clinical trial?

Sage TherapeuticsLead Sponsor
46 Previous Clinical Trials
8,708 Total Patients Enrolled
2 Trials studying Huntington Disease
86 Patients Enrolled for Huntington Disease

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to travel to the study center to complete study visits for the duration of the study.
You are willing to invite a study partner.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: October 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What site did they apply to?
Sage Investigational Site100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria33.3%
Met criteria66.7%